BOSTON: An experimental DNA vaccine has shown promise for the treatment of hypertension, with a three-dose regimen resulting in a sustained reduction in blood pressure in rats without any apparent side effects.
The vaccine, which targets angiotensin II (Ang II), will now be evaluated further, with particular focus on safety, in the hope that it may eventually provide a new therapeutic option for patients with the condition.
DNA vaccines have been evaluated in several recent clinical trials and show the ability to increase antibody titres and mediate therapeutic effects in conditions such as Alzheimer’s disease, obesity, diabetes and cancer…